Description

Eribulin Mesylate CAS NO 441045-17-6 is a synthetic macrocyclic ketone analog of halichondrin B, a marine natural product. It is a potent microtubule dynamics inhibitor with significant therapeutic value in oncology. This active pharmaceutical ingredient (API) is primarily required by pharmaceutical manufacturers and research institutions for the development and production of advanced cancer therapeutics.

Application

• Oncological API Manufacturing: Primary use as the active pharmaceutical ingredient in the commercial production of injectable chemotherapy drugs.
• Metastatic Breast Cancer Treatment: Formulation into finished dosage forms for patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens.
• Liposarcoma Treatment: Utilization in the production of therapies for patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.
• Pharmaceutical Research & Development: Serving as a key reference standard and building block in preclinical and clinical research for novel antimitotic cancer therapies.
• Mechanistic Studies: Used in biochemical and cell biology research to study microtubule dynamics, mitotic arrest, and apoptosis induction.
• Drug Combination Studies: Investigation in combination with other therapeutic agents to explore synergistic effects and new treatment protocols.

Basic Information

Product Name	Eribulin Mesylate
CAS No.	441045-17-6
Molecular Formula	C₄₀H₅₉NO₁₁ • CH₄O₃S
Molecular Weight	826.0 g/mol (mesylate salt)
Synonyms	Eribulin Mesylate; E7389; ER-086526; Halaven (Brand Name); B1939 mesylate; (2R,3R,3aS,7R,8aS,9S,10aR,11S,12R,13aR,13bS)-5-(benzyloxy)-13b-[(2S)-3-[(1,1-dimethylethyl)dimethylsilyl]oxy-2-hydroxypropyl]-9,10a,12-trihydroxy-3,6,8,8a,11,13a-hexamethyl-3a,4,7,8,9,10,10a,11,12,13,13a,13b-dodecahydro-2H-cyclopenta[a]chrysene-2-carboxylic acid methyl ester monomethanesulfonate
EINECS	Contact for details

Quality Control

Our Eribulin Mesylate is manufactured under strict cGMP conditions, ensuring the highest standards of purity and consistency required for pharmaceutical applications. Each batch is supported by a comprehensive Certificate of Analysis (COA) detailing identity, purity, impurity profile, and residual solvents. We adhere to stringent ICH Q3A, Q3B, and Q3C guidelines for impurities. Certificates of Analysis (COA) are available upon request.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C) or as indicated on the label. This product is hygroscopic (moisture-sensitive) and must be kept under inert atmosphere or in a desiccator to maintain stability and potency.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to reference standard
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	98.0% - 102.0% (on anhydrous basis)
Water Content (KF)	≤ 5.0%
Residual Solvents (GC)	Meets ICH Q3C limits
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single unknown impurity ≤ 0.5%
Heavy Metals	≤ 20 ppm
Specific Rotation	[α]²⁰D: +12.0° to +16.0° (c=1, in MeOH)

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.